Skip to main content

Table 1 BRCA1/2 founder mutation frequencies in AJ unselected prostate cancer cases and controls

From: Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer

 

Ref #

185delAG (%)

5382insC (%)

6174delT (%)

Cases

    

Lehrer et al (1998)

13

0/60

n.t.

0/60

Hubert et al (1999)

14

2/87 (2.3%)

0/87

1/87 (1.1%)

Nastiuk et al (1999)

15

1/83 (1.2%)

n.t.

2/82 (2.4%)

Vazina et al (2000)

16

2/87 (2.3%)

2/60 (3.3%)*

1/86 (1.1%)

Hamel et al (this study)

 

0/146

0/146

2/146 (1.4%)

Total

 

5/463 (1.1%)

2/293 (0.68%)

6/461 (1.3%)

Controls

    

Struewing et al (1995)

2

8/858 (0.93%)

0/433

n.t.

Roa et al (1996)

3

34/3108 (1.1%)

4/3116 (0.13%)

47/3085 (1.5%)

Oddoux et al (1996)

4

n.t.

n.t.

12/1255 (0.96%)

Struewing et al (1997)†

8

41/5318 (0.77%)

20/5318 (0.38%)

59/5087 (1.2%)

Hubert et al (1999)

14

2/87 (2.3%)

0/87

1/87 (1.1%)

Total

 

85/9371 (0.91%)

24/8867 (0.27%)

119/9514 (1.3%)

Overall OR (95%CI)

 

1.2 (0.38–2.9)

2.5 (0.29–10)

1.0 (0.37–2.4)

P Value (2-sided)

 

0.62

0.20

0.83

  1. n.t. Not tested Odds ratios were calculated according to the method of Gart. 95% confidence intervals were calculated using the exact Clopper-Pearson method and P values are two-sided Fisher exact tests. *This frequency was reported as significantly different from observations in a control population in the original publication. †Data from this publication were used as control by Vazina et al, 2000.